Health-related quality of life results from the phase III CheckMate 067 study.

ABSTRACT:

Background

Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.

Patients and methods

HRQoL was assessed at weeks 1 and 5 per 6-week cycle for the first 6 months, once every 6 weeks therea

SUBMITTER: Schadendorf D 

PROVIDER: S-EPMC5737813 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature